Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1–Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort

Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials

(2013) Asres Berhan et al.   PLoS One

Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN

(2012) Denes Banhegyi et al.   CURRENT HIV RESEARCH

Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1–Infected Patients With or Without Hepatitis B or C Coinfection

(2012) B. Ha et al.   HIV CLINICAL TRIALS

Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop

(2010) Robert J. Fontana et al.   HEPATOLOGY

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

(2010) Jean-Michel Molina et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral drugs and liver injury

(2009) Vincent Soriano et al.   AIDS

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

(2009) Anthony M Mills et al.   AIDS

Hepatic profile analyses of tipranavir in Phase II and III clinical trials

(2009) Jaromir Mikl et al.   BMC INFECTIOUS DISEASES